Youqiong Ye

Dr. Youqiong Ye

Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JQJingjing Qi
Jingjing Qi
HSHongxiang Sun
Hongxiang Sun
YZYao Zhang
Yao Zhang
ZWZhengting Wang
Zhengting Wang
ZXZhenzhen Xun
Zhenzhen Xun
BSBing Su
Bing Su
Colorectal cancer (CRC) is among the most common malignancies with limited treatments other than surgery. The tumor microenvironment (TME) profiling enables the discovery of potential therapeutic targets. Here, we profile 54,103 cells from tumor and adjacent tissues to characterize cellular composition and elucidate the potential origin and regulation of tumor-enriched cell types in CRC. We demonstrate that the tumor-specific FAP+ fibroblasts and SPP1+ macrophages were positively correlated in 14 independent CRC cohorts containing 2550 samples and validate their close localization by immuno-fluorescent staining and spatial transcriptomics. This interaction might be regulated by chemerin, TGF-β, and interleukin-1, which would stimulate the formation of immune-excluded desmoplasic structure and limit the T cell infiltration. Furthermore, we find patients with high FAP or SPP1 expression achieved less therapeutic benefit from an anti-PD-L1 therapy cohort. Our results provide a potential therapeutic strategy by disrupting FAP+ fibroblasts and SPP1+ macrophages interaction to improve immunotherapy.

26 January 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
YLYao Liu
Yao Liu
ZXZhenzhen Xun
Zhenzhen Xun
KMKun Ma
Kun Ma
SLShuhang Liang
Shuhang Liang
XLXianying Li
Xianying Li
Lianxin LiuLianxin Liu
Lianxin Liu

3 June 2019 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
QHQingsong Hu
Qingsong Hu
Youqiong YeYouqiong Ye
Youqiong Ye
LCLi-Chuan Chan
Li-Chuan Chan
YLYajuan Li
Yajuan Li
KLKe Liang
Ke Liang
Liuqing YangLiuqing Yang
Liuqing Yang

1 March 2018 in Cell Systems
Verified
Journal Article
Closed access
Youqiong YeYouqiong Ye
Youqiong Ye
YXYu Xiang
Yu Xiang
FOFatma Muge Ozguc
Fatma Muge Ozguc
YKYoonjin Kim
Yoonjin Kim
CLChunjie Liu
Chunjie Liu
LHLeng Han
Leng Han

25 September 2017 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
JGJing Gong
Jing Gong
SMShufang Mei
Shufang Mei
CLChunjie Liu
Chunjie Liu
YXYu Xiang
Yu Xiang
Youqiong YeYouqiong Ye
Youqiong Ye
LHLeng Han
Leng Han
Expression quantitative trait locus (eQTL) analysis, which links variations in gene expression to genotypes, is essential to understanding gene regulation and to interpreting disease-associated loci. Currently identified eQTLs are mainly in samples of blood and other normal tissues. However, no database comprehensively provides eQTLs in large number of cancer samples. Using the genotype and expression data of 9196 tumor samples in 33 cancer types from The Cancer Genome Atlas (TCGA), we identified 5 606 570 eQTL-gene pairs in the cis-eQTL analysis and 231 210 eQTL-gene pairs in the trans-eQTL analysis. We further performed survival analysis and identified 22 212 eQTLs associated with patient overall survival. Furthermore, we linked the eQTLs to genome-wide association studies (GWAS) data and identified 337 131 eQTLs that overlap with existing GWAS loci. We developed PancanQTL, a user-friendly database (http://bioinfo.life.hust.edu.cn/PancanQTL/), to store cis-eQTLs, trans-eQTLs, survival-associated eQTLs and GWAS-related eQTLs to enable searching, browsing and downloading. PancanQTL could help the research community understand the effects of inherited variants in tumorigenesis and development.

14 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
Youqiong YeYouqiong Ye
Youqiong Ye
YJYing Jing
Ying Jing
LLLiang Li
Liang Li
GMGordon B. Mills
Gordon B. Mills
LDLixia Diao
Lixia Diao
LHLeng Han
Leng Han
Immune checkpoint blockade therapies have extended patient survival across multiple cancer lineages, but there is a heated debate on whether cancer immunotherapy efficacy is different between male and female patients. We summarize the existing meta-analysis to show inconsistent conclusions for whether gender is associated with the immunotherapy response. We analyze molecular profiling from ICB-treated patients to identify molecular differences for immunotherapy responsiveness. We perform comprehensive analyses for patients from The Cancer Genome Atlas (TCGA) and reveal divergent patterns for sex bias in immune features across multiple cancer types. We further validate our observations in multiple independent data sets. Considering that the majority of clinical trials are in melanoma and lung cancer, meta-analyses that pool multiple cancer types have limitations to discern whether cancer immunotherapy efficacy is different between male and female patients. Future studies should include omics profiling to investigate sex-associated molecular differences in immunotherapy.